Pathogenesis and Reversal Strategies for Cancer Cachexia Using Multi-Omics
Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics
NA · China Medical University, China · NCT07519837
This study uses multiple omics methods and nutritional interventions to try to find causes and reversal strategies for cachexia in adults with gastrointestinal cancers.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | China Medical University, China (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shenyang, Liaoning) |
| Trial ID | NCT07519837 on ClinicalTrials.gov |
What this trial studies
Researchers will combine imaging omics, pathological omics, metabolomics, and metagenomics to build an integrated molecular and clinical model of cancer-related cachexia. Adult patients with gastrointestinal malignancies who undergo biopsy will provide tissue and biological samples for multi-omics analysis. The trial includes an enhanced intervention arm for nutritionally high-risk patients, a standard nutritional intervention positive control, and a placebo negative control to validate intervention effects. Data will be used to map metabolic pathways, identify early biomarkers, and nominate precise therapeutic targets that could reverse muscle and fat loss.
Who should consider this trial
Good fit: Adults (≥18) with histologically or cytologically confirmed gastrointestinal cancers (for example esophageal, hepatocellular, gastric, or cholangiocarcinoma) who can give informed consent and are undergoing primary lesion biopsy or endoscopic biopsy are ideal candidates.
Not a fit: Patients who are pregnant or lactating, have two or more concurrent primary tumors, have contraindications to surgery, or cannot cooperate due to cognitive or psychiatric disorders are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this approach could identify targets and interventions that slow or reverse muscle and fat loss, improving survival, treatment tolerance, and quality of life for patients with cancer cachexia.
How similar studies have performed: Previous observational omics studies have linked certain pathways to cachexia but few interventional programs have demonstrated true reversal, so this combined multi-omics plus interventional approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Signed informed consent form and voluntary participation in this study * Histologically and/or cytologically confirmed diagnosis of cancer * Patients with gastrointestinal malignancies, including: * Esophageal cancer * Hepatocellular carcinoma * Gastric cancer * Cholangiocarcinoma * Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy Exclusion Criteria: * Pregnant or lactating women * Presence of contraindications to surgery * Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate * Presence of two or more concurrent primary tumors
Where this trial is running
Shenyang, Liaoning
- The First Affiliated Hospital of China Medical University — Shenyang, Liaoning, China (RECRUITING)
Study contacts
- Study coordinator: Hanwen Liu
- Email: X18941960007@126.com
- Phone: +86 18941960007
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cachexia, Cancer, Sarcopenia, cancer associated cachexia, Multi-omics Integrated Analysis, Mechanism Exploration and Reversal Strategy Research